Skip to main content
Signal8

IMPACT BIOMEDICAL INC. (IBO) Form 8-K — Nov 18, 2026

$IBOForm 8-KItems 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01Filed Nov 18, 2026, 10:06 AM ET0001493152-26-053017Original filing

Impact BioMedical completed its business combination with Zoar Limited on November 17, 2026, with Impact surviving the merger as a wholly-owned subsidiary of Zoar (PubCo). IBO holders received 8,640,000 PubCo ordinary shares after a 1-for-12.62 reverse split, representing only about 4.80% of PubCo. Control shifted decisively: Zoar shareholder Kanans Visvanats received 167,976,000 shares, or approximately 94.02% of PubCo, with no cash consideration paid. Impact's entire board, CFO, and COO resigned, and a new PubCo board and executive team led by Visvanats was appointed.

Key figures

Dss shares
228000
New ticker
ZOAR
Bmi capital shares
1800000
Bmi capital percent
1.00%
Reverse split ratio
1-for-12.62
Merger completion date
2026-11-17
Zoar shareholder percent
94.02%
Shares to zoar shareholder
167976000
Pubco shares to ibo holders
8640000
Ibo holders percent of pubco
4.80%
Compensation shares to heuszel
22000

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    IMPACT BIOMEDICAL INC. (IBO) Form 8-K — Nov 18, 2026: AI Analysis | Signal8